Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Product for predicting sensitivity of melanoma patient to MAGE-A3 immunotherapy

A MAGE-A3, melanoma technology, applied in the field of biomedicine, can solve problems such as unpredictability, and achieve the effect of high accuracy and good clinical application prospects

Inactive Publication Date: 2022-01-11
QINGDAO MEDINTELL BIOMEDICAL CO LTD
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the immune drug MAGE-A3 therapy is widely used in the adjuvant treatment of clinical melanoma, but it is still difficult to predict which melanoma patients will be sensitive and / or responsive to the immune drug MAGE-A3 therapy. The sensitivity or responsiveness of patients to the immune drug MAGE-A3 remains a great challenge, therefore, the discovery of biologics that can be used to accurately predict the sensitivity and / or responsiveness of melanoma patients to the immune drug MAGE-A3 treatment regimen Biomarkers and their application in pre-treatment screening of melanoma patients is critical to the field and can help individualize treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Product for predicting sensitivity of melanoma patient to MAGE-A3 immunotherapy
  • Product for predicting sensitivity of melanoma patient to MAGE-A3 immunotherapy
  • Product for predicting sensitivity of melanoma patient to MAGE-A3 immunotherapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] Example 1 Screening of genes related to the sensitivity of metastatic melanoma to immune drug MAGE-A3

[0068] 1. Data sources and screening methods

[0069] Patients with clinically diagnosed metastatic melanoma were collected, and none of these patients had received immunotherapy with MAGE-A3 before immunotherapy with MAGE-A3. Before the patients with metastatic melanoma collected above received the immune drug MAGE-A3 immunotherapy, the tumor biopsy tissues of the patients were collected, and the response group (R, responder) or non-response group ( Differentially expressed genes in tumor tissues of NR, non-responder) patients. The MAGE-A3 immunotherapy refers to administering the immune drug MAGE-A3 to patients with metastatic melanoma, and the immune drug MAGE-A3 refers to a substance obtained by dissolving recombinant MAGE-A3 protein in an immunostimulator (AS02B or AS15) . Among them, according to whether the metastatic melanoma is responsive / sensitive to the ...

Embodiment 2

[0073] Application of Differentially Expressed Genes Screened in Example 2 in Predicting Sensitivity of Melanoma to Immunotherapy Drug MAGE-A3

[0074] 1. Experimental method

[0075] For the genes differentially expressed between the responder group and the non-response group screened in Example 1, receiver operating characteristic (ROC) analysis was performed using the R package "pROC" (version 1.15.0), and the receiver operating characteristic (ROC) was calculated. The area under the characteristic curve (AUC) is used to evaluate the accuracy of a single differentially expressed gene, any combination of two differentially expressed genes, and the combination of three differentially expressed genes for predicting the sensitivity of melanoma to the immune drug MAGE-A3 treatment, wherein the The range of AUC value is 0-1;

[0076] Among them, when judging the diagnostic efficacy of a single differentially expressed gene for predicting the sensitivity of melanoma to the immuno...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a product for predicting sensitivity of a melanoma patient to MAGE-A3 immunotherapy. The product comprises a kit. The kit contains reagents for detecting expression levels of markers IL2RG, TMEM56 and / or ELFN1. The provided method and product predict sensitivity of a melanoma patient to MAGE-A3 immunotherapy. The method is simple, has short time and high efficiency, and can provide guidance for individualized medication and selection of treatment schemes.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, in particular, the invention relates to a product for predicting the sensitivity of melanoma patients to MAGE-A3 immunotherapy. Background technique [0002] Melanoma (Melanoma) is a highly malignant tumor derived from melanocytes in the basal layer of the epidermis. skin cancer. In recent years, the morbidity and mortality of melanoma in the world have shown a significant increase trend, accounting for 1%-3% of all malignant tumors, but the growth rate is 6%-7% year by year, and the age of onset is younger It is one of the fastest growing malignant tumors. There are obvious racial differences in the incidence of melanoma, with the highest incidence in whites and lower incidence in yellows and blacks. The main cause of death in melanoma patients is the tumor's susceptibility to rapid metastasis. Melanoma has the characteristics of high malignancy, rapid progression, and early metastasis. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886G01N33/574G01N33/68C12N15/11
CPCC12Q1/6886G01N33/5743G01N33/6869G01N33/68C12Q2600/106C12Q2600/158
Inventor 杨承刚王丹范冰燕郭静李雨晨
Owner QINGDAO MEDINTELL BIOMEDICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com